title: Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with concomitant temozolomide.
abstract: The aim of this study was to evaluate the impact of radiotherapy plus concomitant and adjuvant temozolomide (TMZ), in terms of feasibility and activity, in elderly patients with glioblastoma. From January 2002 to December 2007, 42 consecutive patients with glioblastoma (27 men and 15 women) aged 65 years or more (median age 71.3 years), received radiotherapy plus concomitant and adjuvant TMZ. Nineteen patients (45.2%) had a Karnofsky index >or=80. Thirty-six patients (85.8%) underwent complete or subtotal resection, while 6 patients (14.2%) were only biopsied. All patients received adjuvant radiotherapy within 4 weeks from surgery. Twenty-two patients (54.8%) underwent adjuvant TMZ. Early discontinuation of concomitant TMZ program due to toxicity was observed in 8 patients. Considered variables were: age, Karnofsky index, surgery versus no surgery, radiation dose, and chemotherapy. At a median follow-up of 10.2 months, the 6- and 12-month overall survival rates were 81.9% and 27.8%, respectively. There was a significantly better survival for patients with a performance status according to Karnofsky >80 (p<0.0001). Actuarial progression-free survival at 6- and 12-month was 46.4% and 9.8%, respectively. Globally, the treatment was well tolerated with no treatment-related toxicity in 69% of patients. In conclusion, in elderly patients, the adjuvant chemo-radiotherapy was well tolerated with an acceptable rate of toxicity, and patients with a good performance status had a significantly better survival. However, further prospective trials are needed to confirm these results.
authors.affiliation: Division of Radiotherapy, Arcispedale S'Anna Universitary Hospital, Ferrara, Italy. francesco.fiorica@unife.it
authors.forename: F
authors.initials: F
authors.lastname: Fiorica
authors.forename: M
authors.initials: M
authors.lastname: Berretta
authors.forename: C
authors.initials: C
authors.lastname: Colosimo
authors.forename: A
authors.initials: A
authors.lastname: Stefanelli
authors.forename: S
authors.initials: S
authors.lastname: Ursino
authors.forename: E
authors.initials: E
authors.lastname: Zanet
authors.forename: T
authors.initials: T
authors.lastname: Palmucci
authors.forename: D
authors.initials: D
authors.lastname: Maugeri
authors.forename: M
authors.initials: M
authors.lastname: Malaguarnera
authors.forename: S
authors.initials: S
authors.lastname: Palmucci
authors.forename: M
authors.initials: M
authors.lastname: Grasso
authors.forename: U
authors.initials: U
authors.lastname: Tirelli
authors.forename: F
authors.initials: F
authors.lastname: Cartei
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D001706:Biopsy; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D019635:Neurosurgical Procedures / Q000379:methods; D000077204:Temozolomide; D016896:Treatment Outcome
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide